Molecular insights on post-chemotherapy retinoblastoma by microarray gene expression analysis

Bioinformatics and Biology Insights

Volumn 7, Issue , 2013, Pages 289-306

  Nalini, Venkatesan ^a,b   Segu, Ramya ^c   Deepa, Perinkulam Ravi ^b   Khetan, Vikas ^d   Vasudevan, Madavan ^e   Krishnakumar, Subramanian ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^c Vision Research Foundations   (India)

^d Sri Bhagawan Mahavir Department of Vitreoretina and Ocular Oncology Medical Foundation Sankara Nethralaya   (India)

^e Bionivid Technology Private Limited   (India)

Author keywords

Chemotherapy; Drug resistance; Ect2; Micro array; MYBL2; NCoR1; PRAME; RB

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; EPITHELIAL CELL TRANSFORMING SEQUENCE 2 PROTEIN; MESSENGER RNA; PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ABCC4 GENE; AMINO ACID SEQUENCE; ARTICLE; BIRC5 GENE; CANCER CHEMOTHERAPY; CELL VIABILITY; CHILD; CONTROLLED STUDY; DOWN REGULATION; ECT2 GENE; EZH2 GENE; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; JAK1 GENE; JAK2 GENE; LAMN1 GENE; MALE; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; MYBL2 GENE; NCOR1 GENE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLK2 GENE; PRAME GENE; PRESCHOOL CHILD; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE ANALYSIS; RB1 GENE; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAMN1 GENE; STAT1 GENE; STAT2 GENE; SYK GENE; TUMOR GENE; UPREGULATION;

EID: 84884384754     PISSN: None     EISSN: 11779322     Source Type: Journal    
DOI: 10.4137/BBI.S12494     Document Type: Article

References (57)

1. Dhar SU, Chintagumpala M, Noll C, Chevez-Barrios P, Paysse EA, Plon SE. Outcomes of integrating genetics in management of patients with retinoblastoma. Arch Ophthalmol. 2011;129(11):1428-34.
2. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18(1):12-7.
3. Anteby I, Ramu N, Gradstein L, Miskin H, Pe'er J, Benezra D. Ocular and orbital complications following the treatment of retinoblastoma. Eur J Ophthalmol. 1998;8(2):106-11.
4. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res. 1996;2(9):1499-508.
5. Chan HS, Thorner PS, Haddad G, Gallie BL. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology. 1991;98(9):1425-31.
6. Krishnakumar S, Mallikarjuna K, Desai N, et al. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol. 2004;88(12):1521-6.
7. Kase S, Parikh JG, Rao NA. Expression of alpha-crystallin in Arch Ophthalmol. Feb 2009;127(2):187-92.
8. Kase S, Parikh JG, Rao NA. Expression of heat shock protein 27 and alpha-crystallins in human retinoblastoma after chemoreduction. Br J Ophthalmol. 2009;93(4):541-4.
9. Mohan A, Kandalam M, Ramkumar HL, Gopal L, Krishnakumar S. Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthalmol. 2006;90(7):889-93.
10. Krishnakumar S, Mohan A, Kandalam M, Ramkumar HL, Venkatesan N, Das RR. SRPK1: a cisplatin sensitive protein expressed in retinoblastoma. Pediatr Blood Cancer. 2008;50(2):402-6.
11. Sudhakar J, Venkatesan N, Lakshmanan S, Khetan V, Krishnakumar S, Biswas J. Hypoxic tumor environment in advanced retinoblastoma. Pediatr Blood Canc. 2013. In press.
12. Mitra M, Kandalam M, Sundaram CS, et al. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention. Invest Ophthalmol Vis Sci. 2011;52(8):5441-8.
13. Chakraborty S, Khare S, Dorairaj SK, Prabhakaran VC, Prakash DR, Kumar A. Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics. 2007;90(3):344-53.
14. Ganguly A, Shields CL. Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis. 2010;16:1292-303.
15. Schultz KR, Ranade S, Neglia JP, Ravindranath Y. An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj, Maharashtra, India. Cancer. 1993;72(1):282-6.
16. Murphree AL, Villablanca JG, Deegan WF 3rd, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1348-56.
17. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. Ophthalmology. 2003;110(6):1237-40.
18. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114(11):1321-8.
19. Schueler AO, Jurklies C, Heimann H, Wieland R, Havers W, Bornfeld N. Thermochemotherapy in hereditary retinoblastoma. Br J Ophthalmol. 2003; 87(1):90-5.
20. Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O'Brien JM. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001;119(1):41-8.
21. Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1339-43.
22. Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol. 2002;120(4):460-4.
23. Shields CL, Shelil A, Cater J, Meadows AT, Shields JA. Development of new retinoblastomas after 6cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol. 2003;121(11): 1571-6.
24. Goldie JH. Drug resistance in cancer: a perspective. Cancer Metastasis Rev. 2001;20(1-2):63-8.
25. Wilson MW, Fraga CH, Rodriguez-Galindo C, Hagedorn N, Leggas ML, Stewart C. Expression of the multi-drug resistance proteins and the pregnane X receptor in treated and untreated retinoblastoma. Curr Eye Res. 2009;34(5):386-94.
26. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18(1):41-53, viii.
27. Sastre X, Chantada GL, Doz F, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch pathol Lab Med. 2009;133(8):1199-202.
28. Li W. Volcano plots in analyzing differential expressions with mRNA microarrays. J Bioinform Comput Biol. 2012;10(6):1231003.
29. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48(9):876-8.
30. Kerbel RS, Kobayashi H, Graham CH. Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem. 1994; 56(1):37-47.
31. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275-92.
32. Wilson TR, Longley DB, Johnston PG. Chemoresistance in solid tumours. Ann Oncol. 2006;17(Suppl 10):x315-24.
33. Wilson MW, Fraga CH, Fuller CE, et al. Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest Ophthalmol Vis Sci. 2006;47(4):1269-73.
34. Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329-34.
35. Goellner S, Steinbach D, Schenk T, et al. Childhood acute myelogenous leukaemia: association between PRAME, apoptosis-and MDR-related gene expression. Eur J Cancer. 2006;42(16):2807-14.
36. Srougi MC, Burridge K. The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage. PLoS One. 2011;6(2):e17108.
37. Murphree AL, Triche TJ. An epigenomic mechanism in retinoblastoma: the end of the story? Genome Med. 2012;4(2):15.
38. Hara T, Abe M, Inoue H, et al. Cytokinesis regulator ECT2 changes its conformation through phosphorylation at Thr-341in G2/M phase. Oncogene. 2006;25(4):566-78.
39. Niiya F, Tatsumoto T, Lee KS, Miki T. Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA. Oncogene. 2006;25(6):827-37.
40. Niiya F, Xie X, Lee KS, Inoue H, Miki T. Inhibition of cyclin-dependent kinase 1induces cytokinesis without chromosome segregation in an ECT2 and MgcRacGAP-dependent manner. J Biol Chem. 2005;280(43):36502-9.
41. Tatsumoto T, Xie X, Blumenthal R, Okamoto I, Miki T. Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis. J Cell Biol. 1999;147(5):921-8.
42. Cook DR, Solski PA, Bultman SJ, et al. The ect2 rho Guanine nucleotide exchange factor is essential for early mouse development and normal cell cytokinesis and migration. Genes Cancer. 2011;2(10):932-42.
43. Justilien V, Jameison L, Der CJ, Rossman KL, Fields AP. Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation. J Biol Chem. 2011;286(10):8149-57.
44. Kim JE, Billadeau DD, Chen J. The tandem BRCT domains of Ect2 are required for both negative and positive regulation of Ect2in cytokinesis. J Biol Chem. 2005;280(7):5733-9.
45. Salhia B, Tran NL, Chan A, et al. The guanine nucleotide exchange factors trio, Ect2, and Vav3mediate the invasive behavior of glioblastoma. Am J Pathol. 2008;173(6):1828-38.
46. Sano M, Genkai N, Yajima N, et al. Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients. Oncol Rep. 2006;16(5):1093-8.
47. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199-208.
48. Bankovic J, Stojsic J, Jovanovic D, et al. Identification of genes associated with non-small-cell lung cancer promotion and progression. Lung Cancer. 2010;67(2):151-9.
49. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. Br J Cancer. 2008;99(3): 398-403.
50. Szczepanski MJ, DeLeo AB, Luczak M, et al. PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol. 2013;49(2):144-51.
51. Nazha B, Granner T, Maloney S, Odashiro AN, Antecka E, Burnier MN Jr. Aberrant Nuclear Repressor Coreceptor 1Localization in Human Retinoblastoma. Ophthalmic Res. 2013;49(4):171-6.
52. Jepsen K, Hermanson O, Onami TM, et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell. 2000;102(6):753-63.
53. Li X, McDonnell DP. The transcription factor B-Myb is maintained in an inhibited state in target cells through its interaction with the nuclear corepressors N-CoR and SMRT. Mol Cell Biol. 2002;22(11):3663-73.
54. Calvisi DF, Simile MM, Ladu S, et al. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53. Hepatology. 2011;53(4):1226-36.
55. Sara Pensa GR, Daniela Boselli, Francesco Novelli and Valeria Polianou. STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin? Landes Bioscience; 2009.
56. De Carvalho DD, Binato R, Pereira WO, et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene. 2011;30(2):223-33.
57. Chen X, He D, Dong XD, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(3):2248-56.